Home › Cancro al seno › North Carolina
Studi clinici su Cancro al seno nello stato di North Carolina
91 studi su Cancro al seno cercano partecipanti presso sedi nello stato di North Carolina.
Città nello stato di North Carolina
- Durham64 studi
- Charlotte22 studi
- Winston-Salem14 studi
- Concord5 studi
- Shelby5 studi
- Greensboro5 studi
- Gastonia4 studi
- High Point4 studi
- Greenville4 studi
- Asheville3 studi
- Raleigh3 studi
Testo ufficiale dello studio (inglese)
The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
In reclutamentoVolontari sani benvenuti
Età da 45 a 75 · Tutti i sessi · Aggiornato il 5 ott 2026 · NCT06995898Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- Comprehensive Cancer Center at Wake Forest University (CCCWFU), Winston-Salem
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ott 2026 · NCT02422641A Study of PHST001 in Advanced Solid Tumors
- Duke Cancer Institute, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ott 2026 · NCT06840886The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Duke Cancer Network, Durham
- Cone Health Cancer Center, Greensboro
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05827081Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07059884Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- e altri 6
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Levine Cancer, Charlotte
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07102381Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
- University of North Carolina, Chapel Hill
In reclutamentoFase 2Volontari sani benvenuti
Età da 18 a 45 · Donne · Aggiornato il 1 ott 2026 · NCT05557877A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06369285Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07360314Radiation Therapy and Thymus Function in Young Women With Breast Cancer
- Duke Cancer Center, Durham
In reclutamentoStudio osservazionale
Età da 18 a 50 · Donne · Aggiornato il 29 set 2026 · NCT07725172BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Duke Cancer Center, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06120283Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
- University of North Carolina, Chapel Hill
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Tutte le età · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05440929A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Novant Health Cancer Institute ( Site 0019), Charlotte
- Novant Health Oncology Specialists ( Site 0074), Winston-Salem
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07060807A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Levine Cancer Institute ( Site 0014), Charlotte
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06312176The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Levine Cancer Institute, Albemarle
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
- e altri 11
In reclutamentoFase 3
Età 60 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06377852ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Duke Cancer Institute, Durham
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07007559Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
In reclutamento
Età 30 e oltre · Donne · Aggiornato il 25 set 2026 · NCT02945579Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Atrium Levine Cancer Institute, Charlotte
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07214532Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Charlotte
- Clinical Trial Site, Durham
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07085767A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213791A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Messino Cancer Centers, Asheville
- WakeMed Cancer Care - Waverly Hematology & Medical Oncology, Cary
- University of North Carolina Medical Center, Chapel Hill
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of North Carolina Medical Center, Chapel Hill
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07287098A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Atrium Health, Charlotte
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT05894239Identifying Patterns in the Breath of Individuals With Breast Cancer
- Duke University Medical Cente, Durham
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 74 · Donne · Aggiornato il 18 set 2026 · NCT06512350Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT07340541ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Oncology Specialists of Charlotte Pa, Charlotte
- Carolina Oncology Specialists, Charlotte
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07173751Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07685938Utility of a Mobile Application for Young Women With Breast Cancer
- Atrium Health Levine Cancer, Charlotte
In reclutamento
Età da 18 a 45 · Donne · Aggiornato il 15 set 2026 · NCT07009093A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Duke Cancer Institute, Durham
- Cape Fear Valley Medical Center, Fayetteville
- Cone Health Cancer Center at Wesley Long, Greensboro
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT06492616Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- University of North Carolina at Chapel Hill, Chapel Hill
In reclutamentoStudio osservazionale
Età da 20 a 74 · Donne · Aggiornato il 14 set 2026 · NCT07214610A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Charlotte
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT05123482A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Duke Cancer Institute, Durham
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT03424005A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Duke Cancer Institute, Durham
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06253871A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Levine Cancer Institute, Charlotte
- Novant Health Cancer Institute, Charlotte
- Novant Health Oncology Specialists, Winston-Salem
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT07100106Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Duke Cancer Institute, Durham
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT05315700A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Novant Health Cancer Institute, Charlotte
- Duke Cancer Institute, Durham
- Novant Health Cancer Institute, Winston-Salem
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06790693Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Duke University, Durham
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT05846789Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
- University of North Carolina, Chapel Hill
In reclutamentoFase 2
Età 50 e oltre · Donne · Aggiornato il 3 set 2026 · NCT06902311Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.